GOLDEN RETRIEVER LIFETIME STUDY - DATA AND SAMPLES AVAILABLE FOR RESEARCHThe Golden Retriever Lifetime Study is a longitudinal study established in 2012 with a cohort of 3,044 dogs at full enrollment in 2015. Primary Study endpoints include lymphoma, hemangiosarcoma, high-grade mast cell tumors and osteosarcoma. Secondary Study endpoints cover a variety of diseases affecting the breed, including other cancers. Now in its 10th year, the Study provides a rich data set for researchers from universities, nonprofit and governmental organizations as well as private industry.Dog owners and veterinarians are completing annual questionnaires, clinical exams and sample collection over each dog’s lifetime. These data and samples are now available for research questions in areas such as genetics, disease conditions, environmental factors, nutrition and behavior to improve canine health. While the Study was established to determine risk factors for major cancers, the data and samples can be used to explore many other aspects of canine health. All applications must be received through Fluxx. Interested in data only? Check out our Data Commons before applying to see if our existing datasets meet your needs. RFP Open Period: 11/15/23–1/10/24 |
APPLY FOR: |
|
|
PROPOSAL APPLICATION FLOWCHARTBelow you will find a flowchart that describes the process for a typical university-based research proposal. (This does not apply to the hemangiosarcoma request for proposals.) |
![]() |
|
AVAILABLE SAMPLES |
|
Frequently Asked Questions
The agreement details publication requirements and how the data can and cannot be used. Contact the Foundation with specific questions.
The data is sent as a .csv file.
Please refer to our Application Process Flowchart above.
Acknowledgement: We would like to thank Morris Animal Foundation, its staff members and all participants in the Golden Retriever Lifetime Study, including the dog owners, their golden retrievers and the Study veterinarians who made this work possible.
Funding: The Golden Retriever Lifetime Study and this manuscript were made possible through financial support provided by the Morris Family Foundation, the Mark & Bette Morris Family Foundation, VCA, the V Foundation, Blue Buffalo Company, Petco Love, Zoetis, Antech Inc., Elanco, the Purina Institute, Orvis, the Golden Retriever Foundation, the Hadley and Marion Stuart Foundation, Mars Veterinary, generous private donors and the Flint Animal Cancer Center at Colorado State University. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Endpoint tiers are used to evaluate confidence in each cancer diagnosis.
CONFIDENCE | TIER | CATEGORY |
---|---|---|
DEFINITIVE |
1 |
POSITIVE HISTOLOGY OR CYTOLOGY REVIEWED BY A BOARDCERTIFIED PATHOLOGIST. FOR LYMPHOMA, FLOW CYTOMETRY OR PARR ACCEPTED |
PRESUMPTIVE |
2 |
DIRECT VISUALIZATION OR IMAGING WITHOUT MICROSCOPIC CONFIRMATION. FOR LYMPHOMA, IN-HOUSE CYTOLOGY |
PRESUMPTIVE | 3 (CLINICAL SUSPICION) |
CLINICAL DIAGNOSIS ONLY |
|
APPROVED APPLICATIONS |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|